Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Belgian Life Science Investor Exceeds Expectations With New €125m Fund

Executive Summary

Fund+ has beaten its €100m target to raise €125m for life science investment in Europe – making it the largest private biotech fund in Belgium.

You may also be interested in...

Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH

Emerging Company Profile: Belgium’s Promethera presented preclinical data for HepaStem, its liver-derived stem cell candidate for NASH, fibrosis and acute-on-chronic liver disease, at the AASLD meeting. With what appears to be a solid safety profile, the company hopes to move into clinical studies in the near term.

Snapshot: April Highlights

A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series. 

Transforming Patient Engagement At Novartis

Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action. 


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts